Last reviewed · How we verify
Dilatrend SR capsule — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Dilatrend SR capsule (Dilatrend SR capsule) — Chong Kun Dang Pharmaceutical.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dilatrend SR capsule TARGET | Dilatrend SR capsule | Chong Kun Dang Pharmaceutical | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dilatrend SR capsule CI watch — RSS
- Dilatrend SR capsule CI watch — Atom
- Dilatrend SR capsule CI watch — JSON
- Dilatrend SR capsule alone — RSS
Cite this brief
Drug Landscape (2026). Dilatrend SR capsule — Competitive Intelligence Brief. https://druglandscape.com/ci/dilatrend-sr-capsule. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing